Clinical Implication of EGF A61G Polymorphism in the Risk of Non Small Cell Lung Adenocarcinoma Patients: A Case Control Study

• DOI: 10.7314/apjcp.2015.16.17.7529
• Publication Date: 2016-01-18T02:46:10Z
• Authors: Mirza Masroor; Jain Amit; Jamsheed Javid; Rashid Mir; Y Prasant; A Imtiyaz; Z Mariyam; Anant Mohan; PC Ray; Alpana Saxena
• Keywords: Adult; Male; Risk; Pulmonary and Respiratory Medicine; Lung Neoplasms; Genotype; EGFR; Advancements in Lung Cancer Research; India; Adenocarcinoma of Lung; Adenocarcinoma; Polymorphism, Single Nucleotide; Gene; HER2 Signaling in Breast Cancer Treatment; Small Cell Lung Cancer; 03 medical and health sciences; 0302 clinical medicine; Carcinoma, Non-Small-Cell Lung; Health Sciences; Biomarkers, Tumor; Genetics; Humans; Genetic Predisposition to Disease; Internal medicine; Lung; Biology; Aged; Cancer; Aged, 80 and over; Allele; Epidermal Growth Factor; Epidermal growth factor; Gastroenterology; Middle Aged; Prognosis; 3. Good health; Oncology; Case-Control Studies; FOS: Biological sciences; Medicine; Female; Lung cancer; EGFR Mutations; Receptor

Background: The epidermal growth factor (EGF) plays important roles in non-small cell lung cancer (NSCLC) susceptibility and functional polymorphism the EGF (+61A/G) gene has been linked to increased risk of NSCLC. This study aimed evaluate role +61A/G NSCLC adenocarcinoma (ADC) occurrence survival an Indian population. Materials Methods: casecontrol included 100 histopathologically confirmed patients healthy controls. (A61G) was genotyped by AS-PCR elucidate putative associations with clinical outcomes. association estimated Kaplan-Meier curves. Results: It found that 61AG heterozygous GG homozygous genotype is significantly associated compared AA genotype, [OR 2.61 (1.31-5.18) 3.25 (1.31-8.06), RR 1.51(1.15-2.0) 1.72 (1.08-2.73) RD 23.2 (6.90-39.5) 28.53(7.0-50.1) for AG (p=0.005) (p=0.009)]. Patients G allele exhibited a poor overall survival. median time 61 AA, AG, genotypes 10.5, 7.4, 7.1 months (p=0.02), respectively. + 7.3 (p=0.009). Conclusions: present revealed A61G may be novel independent prognostic marker identify at higher unfavourable outcome.